Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronicles in drug discovery.

V Khurdayan, M Cullell-Young

    Drug News & Perspectives
    |July 22, 2005
    PubMed
    Summary
    This summary is machine-generated.

    New research highlights IDO inhibitors for cancer immunotherapy and chemotherapy enhancement. Other studies explore gamma-secretase inhibitors for Alzheimer's, novel treatments for premature ovarian failure, selective ERbeta agonists for various diseases, and phospholipase A2 inhibitors for inflammatory conditions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.

    ESMO open·2022
    Same author

    Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Reply to the letter to the editor 'treating breast cancer with trabectedin: a new arsenal' by L. Malik.

    Annals of oncology : official journal of the European Society for Medical Oncology·2014
    Same author

    Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2014
    Same author

    Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.

    British journal of cancer·2013
    Same author

    Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.

    Cancer chemotherapy and pharmacology·2013
    Same journal

    New drug discovery and development in India.

    Drug news & perspectives·2013
    Same journal

    Are we living in the end of the blockbuster drug era?

    Drug news & perspectives·2010
    Same journal

    Molecule of the Month. TAK-875.

    Drug news & perspectives·2010
    Same journal

    Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

    Drug news & perspectives·2010
    Same journal

    Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

    Drug news & perspectives·2010
    Same journal

    Trioxaquines: hybrid molecules for the treatment of malaria.

    Drug news & perspectives·2010
    See all related articles

    Area of Science:

    • Oncology
    • Neurology
    • Endocrinology
    • Immunology
    • Pharmacology

    Background:

    • Indoleamine 2,3-dioxygenase (IDO) inhibitors show promise in enhancing anti-tumor immunity and chemotherapy efficacy.
    • Targeting gamma-secretase activity is a key strategy for reducing amyloid-beta production in Alzheimer's disease.
    • Novel therapeutic approaches are needed for premature ovarian failure (POF) beyond current hormone replacement therapy.
    • Selective estrogen receptor beta (ERbeta) agonists are being investigated for inflammatory and cognitive disorders.
    • Phospholipase A2 (PLA2) inhibitors are studied for their potential in treating allergies, asthma, arthritis, and atherosclerosis.

    Purpose of the Study:

    • To summarize recent advancements in IDO inhibitors for cancer treatment.

    Related Experiment Videos

  • To review therapeutic strategies targeting gamma-secretase for Alzheimer's disease.
  • To highlight the need for new treatments for premature ovarian failure (POF).
  • To discuss the therapeutic potential of selective ERbeta agonists.
  • To present the ongoing research on specific PLA2 inhibitors for various inflammatory and cardiovascular diseases.

    • Main Methods:

    • Review of recent brief reports and ongoing research findings.
    • Analysis of preclinical and clinical data on novel therapeutic agents.
    • Exploration of molecular mechanisms of action for targeted therapies.
    • Synthesis of information on drug development for specific disease areas.

    Main Results:

    • IDO inhibitors demonstrate significant antitumor effects by modulating the immune response.
    • Inhibition of gamma-secretase reduces amyloid-beta production, a target for Alzheimer's therapy.
    • Selective ERbeta agonists show potential for treating inflammatory bowel syndrome, endometriosis, and cognitive decline.
    • Specific PLA2 inhibitors are being developed as anti-inflammatory and anti-atherosclerotic agents.

    Conclusions:

    • IDO inhibitors represent a promising avenue for cancer immunotherapy and combination therapy.
    • Gamma-secretase inhibition offers a potential therapeutic strategy for Alzheimer's disease.
    • Selective ERbeta agonists hold promise for a range of estrogen-mediated conditions.
    • Targeted PLA2 inhibition presents opportunities for managing inflammatory and cardiovascular diseases.